arrow
D

Dietger Niederwieser

University of Leipzig
H指数:103
被引数:6.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Decentralized CAR-T production: clinical, economic, and regulatory perspectives. Worldwide Network for Blood & Marrow Transplantation (WBMT) special article

去中心化CAR-T生产:临床、经济和监管视角。世界血液与骨髓移植网络(WBMT)专题文章

2026-09-240
PRE
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results

伊马替尼治疗慢性粒细胞白血病两次尼洛替尼巩固治疗后的无治疗缓解: 3期ENESTPath结果

Leukemia
IF13.4
2026-01-190
PRE
The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients

年龄对初诊多发性骨髓瘤患者自体造血细胞移植后生存和超额死亡率的影响

2026-01-011
OA
Neglected tropical diseases (NTDs) and related infections in hematopoietic cellular therapy (HCT) in adults and children: a survey from the Infectious Diseases Working Party (IDWP) of the European Society of Blood and Marrow Transplantation (EBMT)

忽视的热带疾病(NTDs)及相关感染在成人及儿童造血细胞治疗(HCT)中的应用:欧洲血液与骨髓移植学会(EBMT)感染性疾病工作组(IDWP)的调查

2025-11-220
PRE
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
Correction: Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation

更正:在资源有限国家中,使用非冷冻保存的自体外周血干细胞移植治疗多发性骨髓瘤和淋巴瘤:来自世界骨髓移植联盟的实践考量

2025-06-300
PRE
Setting up a Chimeric Antigen Receptor T Cell Therapy Program: A Framework for Delivery from the Worldwide Network for Blood & Marrow Transplantation

建立嵌合抗原受体T细胞疗法项目:世界造血与骨髓移植网络交付框架

2025-05-230
PRE
A comparison of Cryopreserved and non-Cryopreserved Peripheral Blood Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma: A study from the Chronic Malignancies Working Party of the EBMT

比较冷冻保存与非冷冻保存的外周血造血干细胞在多发性骨髓瘤自体移植中的应用:EBMT慢性恶性疾病工作组的研究

2025-03-070
PRE
10 Year Follow-up of CALGB 10603/Ratify: Midostaurin Versus Placebo Plus Intensive Chemotherapy in Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia Patients Aged 18-60 Years

10年随访研究:CALGB 10603/Ratify试验中,年龄18-60岁新诊断FLT3突变急性髓系白血病患者的米哚妥林与安慰剂联合强化化疗的比较

BLOOD
IF23.1
2024-11-050
PRE
Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT)
2024-08-193
OAAI
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study

首次完全缓解的老年急性髓性白血病患者的造血细胞移植: 一项随机III期研究的结果

2024-08-081
OAAI
Continuous and differential improvement in worldwide access to hematopoietic cell transplantation: activity has doubled in a decade with a notable increase in unrelated and non-identical related donors
2024-05-095
OAAI
Endemic or regionally limited parasitic and fungal infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review
2023-04-018
PRE
An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

造血干细胞移植治疗急性髓系白血病的全球应用分析

2023-04-0112
OAAI
Endemic or regionally limited bacterial and viral infections in haematopoietic stem-cell transplantation recipients: a Worldwide Network for Blood and Marrow Transplantation (WBMT) Review
2023-04-014
PRE
Prognostic Impact of Organomegaly in Mastocytosis: An Analysis of the European Competence Network on Mastocytosis
2023-02-013
OAAI
Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

60岁以上新诊断AML患者的不同治疗策略与共同标准臂 (CSA): 一项随机德国组间研究

2023-01-255
OAAI
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 x 109/L to < 100 x 109/L) at baseline: the final analysis of EXPAND
2022-09-109
OAAI